Search Results

There are 5542 results for: content related to: Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

  1. You have free access to this content
    Mechanisms of Everolimus-Induced Glomerulosclerosis After Glomerular Injury in the Rat

    American Journal of Transplantation

    Volume 5, Issue 12, December 2005, Pages: 2849–2861, C. Daniel, L. Renders, K. Amann, E. Schulze-Lohoff, I.A. Hauser and C. Hugo

    Version of Record online : 18 NOV 2005, DOI: 10.1111/j.1600-6143.2005.01120.x

  2. You have free access to this content
    Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients

    American Journal of Transplantation

    Volume 10, Issue 6, June 2010, Pages: 1401–1413, H. Tedesco Silva Jr., D. Cibrik, T. Johnston, E. Lackova, K. Mange, C. Panis, R. Walker, Z. Wang, G. Zibari and Y. S. Kim

    Version of Record online : 28 APR 2010, DOI: 10.1111/j.1600-6143.2010.03129.x

  3. Influence of Everolimus on Steady-State Pharmacokinetics of Cyclosporine in Maintenance Renal Transplant Patients

    The Journal of Clinical Pharmacology

    Volume 45, Issue 7, July 2005, Pages: 781–791, Dr Klemens Budde, Dr Gustav Lehne, Dr Michael Winkler, Dr Lutz Renders, Dr Arno Lison, Dr Lutz Fritsche, Dr Jean-Paul Soulillou, Dr Per Fauchald, Dr Hans-Hellmut Neumayer, Dr Jaques Dantal and Behalf of the RADW 102 Renal Transplant Study Group

    Version of Record online : 25 MAR 2013, DOI: 10.1177/0091270005277196

  4. You have free access to this content
    Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain

    Liver Transplantation

    Volume 21, Issue 8, August 2015, Pages: 1056–1065, Itxarone Bilbao, Magdalena Salcedo, Miguel Angel Gómez, Carlos Jimenez, Javier Castroagudín, Joan Fabregat, Carolina Almohalla, Ignacio Herrero, Valentín Cuervas-Mons, Alejandra Otero, Angel Rubín, Manuel Miras, Juan Rodrigo, Trinidad Serrano, Gonzalo Crespo, Manuel De la Mata, Javier Bustamante, M. Luisa Gonzalez-Dieguez, Antonia Moreno, Isidoro Narvaez, Magda Guilera and for the EVEROLIVER study group

    Version of Record online : 24 JUL 2015, DOI: 10.1002/lt.24172

  5. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

    Annals of the New York Academy of Sciences

    Volume 1291, Issue 1, July 2013, Pages: 14–32, David Lebwohl, Özlem Anak, Tarek Sahmoud, Judith Klimovsky, Ingrid Elmroth, Tomas Haas, Joseph Posluszny, Stephen Saletan and William Berg

    Version of Record online : 9 MAY 2013, DOI: 10.1111/nyas.12122

  6. Blood Concentrations of Everolimus Are Markedly Increased by Ketoconazole

    The Journal of Clinical Pharmacology

    Volume 45, Issue 5, May 2005, Pages: 514–528, Dr J. M. Kovarik, Dr D. Beyer, Dr M. N. Bizot, Dr Q. Jiang, Dr M. Shenouda and Dr R. L. Schmouder

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270005275368

  7. You have free access to this content
    Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure–Effect Modeling

    American Journal of Transplantation

    Volume 4, Issue 12, December 2004, Pages: 2126–2131, Randall C. Starling, Joshua M. Hare, Paul Hauptman, Kenneth R. McCurry, Hartmut W. Mayer, John M. Kovarik and Heinz Schmidli

    Version of Record online : 4 OCT 2004, DOI: 10.1046/j.1600-6143.2004.00601.x

  8. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial

    American Journal of Transplantation

    J. W. de Fijter, H. Holdaas, O. Øyen, J.-S. Sanders, S. Sundar, F. J. Bemelman, C. Sommerer, J. Pascual, Y. Avihingsanon, C. Pongskul, F. Oppenheimer, L. Toselli, G. Russ, Z. Wang, P. Lopez, J. Kochuparampil, J. M. Cruzado, M. van der Giet and on behalf of the ELEVATE Study Group

    Version of Record online : 14 FEB 2017, DOI: 10.1111/ajt.14186

  9. Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 32, Issue 4, April 2012, Pages: 383–396, Chad M. Barnett

    Version of Record online : 27 MAR 2012, DOI: 10.1002/j.1875-9114.2012.01084.x

  10. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine

    Clinical Pharmacology & Therapeutics

    Volume 69, Issue 1, January 2001, Pages: 48–56, John M. Kovarik, Barry D. Kahan, Bruce Kaplan, Marc Lorber, Michael Winkler, Marisel Rouilly, Christophe Gerbeau, Natalie Cambon, Robert Boger, Christiane Rordorf and on behalf of the Everolimus Phase 2 Study Group

    Version of Record online : 5 JAN 2001, DOI: 10.1067/mcp.2001.112969

  11. You have full text access to this OnlineOpen article
    Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis

    Cancer Medicine

    Volume 2, Issue 6, December 2013, Pages: 862–871, Kenya Yamanaka, Marius Petrulionis, Shibo Lin, Chao Gao, Uwe Galli, Susanne Richter, Susanne Winkler, Philipp Houben, Daniel Schultze, Etsuro Hatano and Peter Schemmer

    Version of Record online : 22 OCT 2013, DOI: 10.1002/cam4.150

  12. You have free access to this content
    Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation

    Transplant International

    Volume 28, Issue 1, January 2015, Pages: 42–51, Lars Mjörnstedt, Søren Schwartz Sørensen, Bengt von zur Mühlen, Bente Jespersen, Jesper M. Hansen, Claus Bistrup, Helene Andersson, Bengt Gustafsson, Dag Solbu and Hallvard Holdaas

    Version of Record online : 30 SEP 2014, DOI: 10.1111/tri.12437

  13. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data

    Clinical Transplantation

    Volume 19, Issue 2, April 2005, Pages: 145–152, Marc I Lorber, Claudio Ponticelli, John Whelchel, Hartmut W Mayer, John Kovarik, Yulan Li and Heinz Schmidli

    Version of Record online : 4 FEB 2005, DOI: 10.1111/j.1399-0012.2005.00326.x

  14. You have free access to this content
    Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial

    American Journal of Transplantation

    Volume 13, Issue 5, May 2013, Pages: 1203–1216, H. J. Eisen, J. Kobashigawa, R. C. Starling, D. F. Pauly, A. Kfoury, H. Ross, S.-S. Wang, B. Cantin, A. Van Bakel, G. Ewald, S. Hirt, H. Lehmkuhl, A. Keogh, M. Rinaldi, L. Potena, A. Zuckermann, G. Dong, C. Cornu-Artis and P. Lopez

    Version of Record online : 22 FEB 2013, DOI: 10.1111/ajt.12181

  15. You have free access to this content
    Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results

    Liver Transplantation

    Volume 12, Issue 11, November 2006, Pages: 1640–1648, Gary Levy, Heinz Schmidli, Jeffrey Punch, Elizabeth Tuttle-Newhall, David Mayer, Peter Neuhaus, Didier Samuel, Bjorn Nashan, Juergen Klempnauer, Alan Langnas, Yvon Calmus, Xavier Rogiers, Michael Abecassis, Richard Freeman, Maarten Sloof, John Roberts and Lutz Fischer

    Version of Record online : 5 APR 2006, DOI: 10.1002/lt.20707

  16. You have free access to this content
    The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial

    American Journal of Transplantation

    Volume 15, Issue 7, July 2015, Pages: 1967–1975, S. Arora, A. K. Andreassen, B. Andersson, F. Gustafsson, H. Eiskjær, H. E. Bøtker, G. Rådegran, E. Gude, D. Ioanes, D. Solbu, V. Sigurdardottir, G. Dellgren, I. Erikstad, O. G. Solberg, T. Ueland, P. Aukrust, L. Gullestad and on behalf of the SCHEDULE (SCandinavian HEart transplant everolimus De novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators

    Version of Record online : 17 MAR 2015, DOI: 10.1111/ajt.13214

  17. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine

    Clinical Transplantation

    Volume 27, Issue 2, March–April 2013, Pages: 217–226, Fuad S. Shihab, Diane Cibrik, Laurence Chan, Yu Seun Kim, Mario Carmellini, Rowan Walker, Gazi Zibari, James Pattison, Catherine Cornu-Artis, Zailong Wang and Helio Tedesco-Silva Jr

    Version of Record online : 12 DEC 2012, DOI: 10.1111/ctr.12045

  18. You have free access to this content
    Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation

    American Journal of Transplantation

    Volume 12, Issue 10, October 2012, Pages: 2744–2753, L. Mjörnstedt, S. S. Sørensen, B. von zur Mühlen, B. Jespersen, J. M. Hansen, C. Bistrup, H. Andersson, B. Gustafsson, L.H. Undset, H. Fagertun, D. Solbu and H. Holdaas

    Version of Record online : 19 JUL 2012, DOI: 10.1111/j.1600-6143.2012.04162.x

  19. Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice

    British Journal of Pharmacology

    Volume 173, Issue 23, December 2016, Pages: 3359–3371, Ammar Kurdi, Mireille De Doncker, Arthur Leloup, Hugo Neels, Jean-Pierre Timmermans, Katrien Lemmens, Sandra Apers, Guido R Y De Meyer and Wim Martinet

    Version of Record online : 23 OCT 2016, DOI: 10.1111/bph.13626

  20. You have free access to this content
    Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study

    American Journal of Transplantation

    Volume 12, Issue 6, June 2012, Pages: 1528–1540, K. Budde, F. Lehner, C. Sommerer, W. Arns, P. Reinke, U. Eisenberger, R. P. Wüthrich, S. Scheidl, C. May, E.-M. Paulus, A. Mühlfeld, H. H. Wolters, K. Pressmar, R. Stahl, O. Witzke and On behalf of the ZEUS Study Investigators

    Version of Record online : 5 MAR 2012, DOI: 10.1111/j.1600-6143.2012.03994.x

    Corrected by:

    Erratum

    Vol. 12, Issue 11, 3165, Version of Record online: 27 OCT 2012